## DT03 Rec'd PCT/PTO 0 9 SEP 2004

		DEPARTMENT OF COMMERCE NT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 21026YP								
D	ESIGNATED/ELECTEI		U.S. APPLICATION NO. (If known, see 37 CFR 1.5)								
C	ONCERNING A FILING	G UNDER 35 U.S.C. 371	10/507239								
		NTERNATIONAL FILING DATE 7 March 2003	PRIORITY DATE CLAIMED 13 March 2002								
TITLE OF INVENTION											
FLUORINATED 4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS											
APPLICANT(S) FOR DO/EO/US Robert S. Meissnerand James J. Perkins											
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:											
2.	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.										
3.	This is an express request to begin national examination procedures [35 U.S.C. 371(f)]. The submission must include items (5), (6), (9) and (19) indicated below.										
4. <b>X</b>	The US has been elected (PCT Article 31).										
5.	A copy of the International Application as filed [35 U.S.C. 371(c)(2)]  a. is attached hereto (required only if not communicated by the International Bureau).										
	b has been communicated by the International Bureau.										
6.	c. is not required, as the application was filed in the United States Receiving Office (RO/US).  An English language translation of the International Application as filed [35 U.S.C. 371(c)(2)].										
7.	Amendments to the claims of the International Application under PCT Article 19 [35 U.S.C. 371(c)(3)].										
		d hereto (required only if not communicated by the International Bureau).									
		ed by the International Bureau.									
	d. have not been made; ho	owever, the time limit for making such amendments has NOT expired.  and will not be made.									
8.	An English language translation of the amendments to the claims under PCT Article 19 [35 U.S.C. 371(c)(3)].										
9.		An oath or declaration of the inventor(s) [35 U.S.C. 371(c)(4)].									
10.	An English language translation of the annexes to the International Preliminary Examination Report under PCT										
Items 1	Article 36 [35 U.S.C. 371(c)(5 l1 to 18 below concern other d	opple locument(s) or information include	d:								
11.	An Information Disclosure Sta	atement under 37 CFR 1.97 and 1.98.									
12.	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.										
13.	A FIRST preliminary amendment.										
14.	A SECOND or SUBSEQUENT preliminary amendment.										
15.											
16.	6. A power of attorney and/or change of address letter.										
17. 🔲	A computer-readable form of	the sequence listing in accordance wit	h PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.								
18.	Other items or information:	DATE OF DEPOSIT September 9, 2									
		EXPRESS MAIL NO. <u>EL989590708US</u> I HEREBY CERTIFY THAT THIS CORRESPONDEN BEING DEPOSITED WITH THE UNITED STATES P	OSTAL								
		SERVICE AS EXPRESS MAIL "POST OFFICE TO ADD ON THE ABOVE DATE IN AN ENVELOPE ADDRES COMMISSIONER FOR PATERITS, P.O. BOX 14: ALEXANDRIA, VIRGINA 23313-1450.	SED TO								
Page 1 of	2	MAILED BY A ON YOUR OW	2								
		DATE SEPT COMPARE ATTACKED	orm "TransLetter (DO-EO-US)" (PCT Folder), Merck & Co., Inc., 1/1/2004								

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)		INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER						
10/507239 PCT/US03/08277 21026					21026	YP				
19. X The following fees are submitted:						CALCULATIONS	PTO USE ONLY			
BASIC NATIONAL FEE [3										
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee [37 CFR 1.445(a)(2)] paid to USPTO and										
International Search Rep	0.00									
International preliminary USPTO but Internationa	0.00		٠							
International preliminar international search fee	0.00									
International preliminar but all claims did not sa	0.00									
International preliminar claims satisfied provisio	0.00									
	=	\$100.00								
Surcharge of \$130.00 for earliest claimed priority of	the									
Claims	Number File	ed	Number Extra	Rate						
Total Claims	41	- 20 =	21	X \$18.0	00	\$378.00				
Independent Claims	3	- 3 =	0	X \$86.0	00	\$0.00				
Multiple dependent claim	n(s) (if applicable)	)		+ \$290.0	00	\$0.00				
	ח	FOTAL	OF ABOVE CALC	ULATIONS	=	\$478.00				
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.										
above are reduced by	=	\$478.00								
Processing fee of \$130.00 from the earliest claimed	+									
	=	\$478.00								
Fee for recording the enc accompanied by an appro										
1 3. 11		\$478.00								
	$\dashv$	Amount to be								
						refunded				
						charged				
a. A check in the amount of \$ to cover the above fees is enclosed.										
b. Please charge my Deposit Account No. 13-2755 in the amount of \$478.00 to cover the above fees.  A duplicate copy of this sheet is enclosed.										
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to the Deposit Account No. 13-2755. A duplicate copy of this sheet is enclosed.										
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive										
[37 CFR 1.137(a) or (b)] must be filed and granted to restore the application to pending status.										
SEND ALL CORRESPONDENCE TO:  Customer No. 000210										
MERCK & CO., INC.			6	<b>D</b> -		7 00				
Patent Department, RY P.O. Box 2000	<u>~_ (</u>	1. Shalin	aski_							
126 East Lincoln Avenue										
Rahway, New Jersey 0	7065-0970		<u>Pa</u>	atricia A. Shat	tynski	i				
DAME Contourband of	004			AME			·			
DATE: September 9, 20		-	42	3,109						
PHONE #: <u>(732) 594-1</u>	ON N	NUMBER								